Application of medicine composition in preparation of medicines for preventing or treating fatty liver

A composition and fatty liver technology, applied in the field of medicine, to achieve the effects of improving animal liver lesions, preventing and treating the occurrence and development of animal liver lesions, and alleviating the degree of animal liver lesions

Active Publication Date: 2013-09-18
SICHUAN JISHENGTANG PHARMLS
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CN1347714A discloses a kind of pharmaceutical composition for the treatment of diabetic nephropathy, and this composition is made up of Radix Astragali, Ligustrum lucidum, leech, rhubarb, Radix Pseudostellariae, Lycium barbarum, but above-mentioned pharmaceutical composition is used for preventing and treating fatty liver, currently Not yet reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of medicine composition in preparation of medicines for preventing or treating fatty liver
  • Application of medicine composition in preparation of medicines for preventing or treating fatty liver
  • Application of medicine composition in preparation of medicines for preventing or treating fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1. The effect of the pharmaceutical composition on the fatty liver model of acute carbon tetrachloride liver injury in mice

[0047] 1. Experimental method

[0048] Male mice of Kunming species were randomly divided into 6 groups according to body weight, 12 in each group, which were respectively normal group, model group, and positive drug were clinically commonly used ursodeoxycholic acid capsule group, pharmaceutical composition (according to embodiment six Preparation) low, medium and high dose groups (0.5g drug / kg body weight, 1g drug / kg body weight, 2g drug / kg body weight). The test product group was administered by intragastric administration, 1 time / day, the normal group and the model group were given equal-volume distilled water, and the volume of intragastric administration was 0.2ml / 10g body weight, and the administration was continued for 10 days; on the 10th day, except for the blank group, For the rest of the animals, gavage mice with 0.15% car...

Embodiment 2

[0083] Example 2. The Effect of the Pharmaceutical Composition on the Fatty Liver Model of Mouse Acute Ethionine Liver Injury

[0084] 1. Experimental method

[0085]Male mice of Kunming species were randomly divided into 6 groups according to body weight, 12 in every group, respectively normal group, model group, positive drug ursodeoxycholic acid capsule group, pharmaceutical composition (prepared according to embodiment six) low, medium , high dose group (0.5g drug / kg body weight, 1g drug / kg body weight, 2g drug / kg body weight). The test product group was administered by intragastric administration, 1 time / day, the normal group and the model group were given equal-volume distilled water, and the volume of intragastric administration was 0.2ml / 10g body weight, and the administration was continued for 10 days; on the 10th day, except for the blank group, The rest of the animals were gavaged with 0.2% ethionine aqueous solution, and after fasting for 24 hours, the eyeballs of...

Embodiment 3

[0115] Example 3. Effect of the pharmaceutical composition on the acute alcoholic fatty liver model in mice

[0116] 1. Experimental method

[0117] Male mice of Kunming species were randomly divided into 6 groups according to body weight, 14 in every group, respectively normal group, model group, positive drug ursodeoxycholic acid capsule group, pharmaceutical composition (prepared according to embodiment six) low, medium , high dose group (0.5g drug / kg body weight, 1g drug / kg body weight, 2g drug / kg body weight). Except for the blank group, all other groups were given Luzhou Laojiao liquor with an alcohol content of 52% by intragastric administration, with a volume of 12ml / kg body weight, once a day, for 17 consecutive days. -Gavage administration started at 5 hours, the test product group was given the corresponding drug by gavage, 1 time / day, the blank group and the model group were given equal volumes of distilled water, the volume of gavage was 0.2ml / 10g body weight, co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a medicine composition in preparation of medicines for preventing or treating fatty liver. The medicine composition is mainly composed of the six traditional Chinese medicines including astragalus membranaceus, glossy privet fruit, leech, rheum officinale, radix pseudostellariae and barbary wolfberry fruit. The medicine composition has the functions of reducing the index values of serum triglyceride (TG), total cholesterol (TCH), TG (triglyceride) in liver tissues and the like in a fatty liver model, increasing the index values of high-density lipoprotein (HDL) in serum and the like, and reducing the index values of alanine aminotransferase (ALT), malondialdehyde (MDA), glutathione (GSH) and the like in the liver tissues. Simultaneously, the medicine composition is further capable of reducing the degrees of the vacuolar degeneration, debonding degeneration, fatty degeneration, diffuse tissue necrosis and inflammatory cell diffuse infiltration of liver tissues in the fatty liver models of rats and mice. The results prove that the medicine composition has a definite curative effect on fatty liver.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a pharmaceutical composition in the preparation of medicines for preventing or treating fatty liver. Background technique [0002] The liver is an important place for fat metabolism. When the liver's ability to synthesize fat and / or reduce its ability to transport into the blood, excessive accumulation of lipids (mainly triglycerides) in the liver exceeds 5% of the weight of the liver, or more than 50% histologically When the liver parenchyma becomes fatty, it is fatty liver. Fatty liver is not an independent disease, but fatty degeneration of the liver caused by various diseases and reasons. The most common causes are obesity, alcoholism, and diabetes; followed by malnutrition, drug poisoning, pregnancy, and genetics. [0003] Fatty liver is a common clinical phenomenon rather than an independent disease. Its clinical manifestations are asymptomatic in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/815A61P1/16A61K35/62
Inventor 柯潇高小平吴建明
Owner SICHUAN JISHENGTANG PHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap